Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Predicting CAP in patients with intermediate PSA using modified PSA indices.

A Zisman1, D Leibovici, J Kleinmann

  • 1Urology Department, Assaf-Harofeh Medical Centre, Zerifin, Israel.

The Canadian Journal of Urology
|January 11, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First Search for Axion Dark Matter with a MADMAX Prototype.

Physical review letters·2025
Same author

First Search for Dark Photon Dark Matter with a madmax Prototype.

Physical review letters·2025
Same author

Comparative Analysis of Analog and Digital Chest Tube Drainage Systems Using a High-Fidelity 3D-Printed Neonatal Chest Model.

Pediatric pulmonology·2025
Same author

Probing Strangeness Hadronization with Event-by-Event Production of Multistrange Hadrons.

Physical review letters·2025
Same author

Measurements of Chemical Potentials in Pb-Pb Collisions at sqrt[s_{NN}]=5.02  TeV.

Physical review letters·2024
Same author

Observation of Medium-Induced Yield Enhancement and Acoplanarity Broadening of Low-p_{T} Jets from Measurements in pp and Central Pb-Pb Collisions at sqrt[s_{NN}]=5.02  TeV.

Physical review letters·2024
Same journal

Smarter, Not More: The Rationale for Reducing Systematic Cores in the MRI-Targeted Biopsy Era.

The Canadian journal of urology·2026
Same journal

Ten Years of Progress in Advanced Prostate Cancer at the AUA.

The Canadian journal of urology·2026
Same journal

Electroacupuncture for sperm improvement in varicocele: a case report.

The Canadian journal of urology·2026
Same journal

Transperineal approach for penetrating injury of corpus spongiosum and bulbous urethra caused by vesicourethral foreign body: a case report.

The Canadian journal of urology·2026
Same journal

Penile fracture and concomitant severe urethral trauma-a case report and discussion of surgical approach.

The Canadian journal of urology·2026
Same journal

Management of retained bullet fragments from posterior urethra after gunshot wound: a case report.

The Canadian journal of urology·2026
See all related articles

A new prostate-specific antigen (PSA) index, PSA-PZ, effectively predicts prostate cancer in men with intermediate PSA levels. This index can help spare unnecessary biopsies in select patients, particularly those with negative digital rectal exams.

Area of Science:

  • Urology
  • Oncology
  • Biomarkers

Background:

  • Prostate-specific antigen (PSA) is a key biomarker for prostate cancer detection.
  • Differentiating between benign prostatic hyperplasia and prostate cancer in men with intermediate PSA levels (4-10 ng/ml) remains challenging.
  • Existing PSA indices may not fully capture the predictive value in specific patient subgroups.

Purpose of the Study:

  • To introduce and evaluate a novel PSA index, the peripheral zone fraction PSA (PSA-PZ).
  • To assess the predictive accuracy of PSA-PZ in identifying prostate cancer in patients with intermediate PSA levels.
  • To determine if PSA-PZ can help reduce unnecessary prostate biopsies.

Main Methods:

  • Calculated total prostate volume and transition zone volume in 273 patients with serum PSA 4-10 ng/ml.

Related Experiment Videos

  • Developed the PSA-PZ index using the formula: serum PSA * ((Total gland volume - Transition Zone volume) / Total gland volume).
  • Assessed specificity, sensitivity, and predictive values of PSA, PSA density (PSAD), PSA-transition zone (PSA-TZ), and PSA-PZ at various cutoff points.

    • Main Results:

    • PSA-PZ demonstrated effectiveness in predicting prostate cancer, particularly in digital rectal exam (DRE)-negative patients with serum PSA 4-10 ng/ml.
    • A PSA-PZ cutoff of 1.5 ng/ml suggested that biopsies could be spared without missing any cancer cases.
    • The distribution and predictive performance of PSA-PZ were analyzed.

    Conclusions:

    • The PSA-PZ index is a straightforward and clinically convenient tool for prostate cancer risk assessment.
    • PSA-PZ is recommended for use in DRE-negative patients with large prostates and serum PSA levels between 4-10 ng/ml.
    • This index has the potential to optimize the decision-making process regarding prostate biopsies.